Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaccination for Parkinson's disease.
Schneeberger A, Mandler M, Mattner F, Schmidt W. Schneeberger A, et al. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S11-3. doi: 10.1016/S1353-8020(11)70006-2. Parkinsonism Relat Disord. 2012. PMID: 22166404 Review.
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E. Mandler M, et al. Among authors: schneeberger a. Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14. Acta Neuropathol. 2014. PMID: 24525765 Free PMC article.
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E. Mandler M, et al. Among authors: schneeberger a. Mol Neurodegener. 2015 Mar 19;10:10. doi: 10.1186/s13024-015-0008-9. Mol Neurodegener. 2015. PMID: 25886309 Free PMC article.
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, Lührs P, Schneeberger A, von Bonin A, Mattner F, Schmidt W, Staffler G. Galabova G, et al. Among authors: schneeberger a. PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014. PLoS One. 2014. PMID: 25474576 Free PMC article.
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines.
Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, Willbold D, Schneeberger A, Schmidt W, Mattner F. Mandler M, et al. Among authors: schneeberger a. PLoS One. 2015 Jan 22;10(1):e0115237. doi: 10.1371/journal.pone.0115237. eCollection 2015. PLoS One. 2015. PMID: 25611858 Free PMC article.
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.
Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA. Mandler M, et al. Among authors: schneeberger a. Alzheimers Dement. 2019 Sep;15(9):1133-1148. doi: 10.1016/j.jalz.2019.02.002. Epub 2019 Aug 1. Alzheimers Dement. 2019. PMID: 31378574 Free PMC article.
Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease.
Schneeberger A, Hendrix S, Mandler M, Ellison N, Bürger V, Brunner M, Frölich L, Mimica N, Hort J, Rainer M, Imarhiagbe D, Kurz A, Peters O, Gertz HJ, Tierney L, Mattner F, Schmidt W, Dubois B. Schneeberger A, et al. J Prev Alzheimers Dis. 2015;2(2):103-114. doi: 10.14283/jpad.2015.63. J Prev Alzheimers Dis. 2015. PMID: 29231230
196 results